Company intelligence / Profile preview

Enliven Therapeutics

Boulder, Colorado, United Statesenliventherapeutics.com ↗

Ownership: Public · ELVN
Employees: ~62
Development stage: Other

Overview

Enliven Therapeutics has two main clinical candidates in Phase I trials. ELVN‑001 targets BCR‑ABL for CML and has shown promise in preclinical studies; ELVN‑002 targets HER2-driven cancers, including NSCLC and solid tumors, with selectivity for CNS penetration. Both are designed to address resistance, improve safety, and offer better patient convenience compared to existing therapies[1][7]. No pivotal efficacy data have been published yet.

Therapeutic areas: Oncology
Modalities: Small molecules (specifically kinase inhibitors)[1][3][4]
Industry: Biotech

Drug pipeline

4 assets

relcobatinib

3 more assets in the full pipeline.

Financials

Market cap: $3.3B
Total revenue: $0
Enterprise value: $2.4B

Beyond the preview

Go deeper on Enliven Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enliven Therapeutics.